As of close of business last night, Cardiol Therapeutics Inc’s stock clocked out at $1.96, down -4.85% from its previous closing price of $2.06. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 863576 shares were traded.
Ratios:
To gain a deeper understanding of CRDL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.29 and its Current Ratio is at 5.29. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDL now has a Market Capitalization of 127.11M and an Enterprise Value of 97.38M.
Stock Price History:
Over the past 52 weeks, CRDL has reached a high of $2.16, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is 1.1806, while the 200-Day Moving Average is calculated to be 0.9482.
Shares Statistics:
It appears that CRDL traded 307.89K shares on average per day over the past three months and 653.98k shares per day over the past ten days. A total of 64.04M shares are outstanding, with a floating share count of 62.09M. Insiders hold about 4.64% of the company’s shares, while institutions hold 10.64% stake in the company. Shares short for CRDL as of Feb 15, 2024 were 173.54k with a Short Ratio of 0.56, compared to 119.62k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.27% and a Short% of Float of 0.28%.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.09 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.09, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.29 and -$0.35 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.35, with 3 analysts recommending between -$0.26 and -$0.41.
